Central Pacific Bank Trust Division Sells 160 Shares of Hologic, Inc. (NASDAQ:HOLX)

Central Pacific Bank Trust Division reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 15.8% during the third quarter, HoldingsChannel reports. The fund owned 854 shares of the medical equipment provider’s stock after selling 160 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Hologic were worth $70,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Innealta Capital LLC bought a new stake in Hologic in the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. bought a new stake in Hologic in the 1st quarter valued at about $37,000. Sunbelt Securities Inc. bought a new stake in Hologic in the 2nd quarter valued at about $37,000. Cranbrook Wealth Management LLC bought a new stake in Hologic in the 2nd quarter valued at about $47,000. Finally, Mather Group LLC. bought a new stake in Hologic in the 1st quarter valued at about $48,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of research reports. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday. StockNews.com cut Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. Stephens reiterated an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, September 17th. Finally, JPMorgan Chase & Co. upped their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.27.

Insiders Place Their Bets

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock valued at $1,469,973 over the last quarter. 1.75% of the stock is owned by corporate insiders.

Hologic Price Performance

Shares of HOLX stock traded up $1.02 during trading on Friday, hitting $80.24. The company had a trading volume of 1,245,584 shares, compared to its average volume of 1,600,160. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock’s 50-day moving average is $81.24 and its two-hundred day moving average is $77.39. The stock has a market capitalization of $18.73 billion, a price-to-earnings ratio of 40.94, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.93 earnings per share. As a group, analysts predict that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.